Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
NCT03996486 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2019-10-22
Summary
The purpose of this study is to investigate the safety of a test drug to treat hemophilia in adult men.
Conditions
Interventions
- DRUG
-
BAY1093884
Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-28
- Primary Completion
- 2020-05-29
- Completion
- 2020-07-31
- FDA Drug
- Yes
More Related Trials
-
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
NCT01625390 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
NCT01580293 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
NCT03588299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
NCT01029340 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
NCT06349473 ·Status: RECRUITING ·Phase: PHASE1
-
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
NCT00979238 ·Status: COMPLETED ·Phase: PHASE1
-
Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
NCT01921855 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BAX 888 in Male Adults With Severe Hemophilia A
NCT03370172 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
BAY81-8973 Pediatric Safety and Efficacy Trial
NCT01311648 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
NCT01233258 ·Status: COMPLETED ·Phase: PHASE3
-
PF-06741086 Multiple Dose Study in Severe Hemophilia
NCT02974855 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
NCT03995784 ·Status: COMPLETED ·Phase: PHASE2
-
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 ·Status: COMPLETED
-
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
NCT03307980 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
NCT00629837 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
NCT05147662 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
NCT00623480 ·Status: COMPLETED ·Phase: PHASE3
-
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
NCT02453542 ·Status: RECRUITING
-
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
NCT00956345 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
NCT01228669 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
NCT05709288 ·Status: RECRUITING ·Phase: PHASE1
-
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
NCT00621673 ·Status: TERMINATED ·Phase: PHASE4
-
Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222
NCT01653639 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male
NCT02919800 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
NCT06700096 ·Status: RECRUITING ·Phase: PHASE3